[Prevention of GI bleeding due to antiplatelet agents: a labyrinth!].
Bretagne
Jean-François
JF
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects* / Q000627:therapeutic use; D000077144:Clopidogrel; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000627:therapeutic use; D000077402:Pantoprazole; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D000077144:Clopidogrel; D000077402:Pantoprazole; D009853:Omeprazole; D013988:Ticlopidine; D001241:Aspirin